RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Urinary biomarkers in women with refractory urgency urinary incontinence randomized to sacral neuromodulation versus onabotulinumtoxinA compared to controls
Richter, H. E., Moalli, P., Amundsen, C. L., Malykhina, A. P., Wallace, D., Rogers, R., Myers, D., Paraiso, M., Albo, M., Shi, H., Nolen, T., Meikle, S., & R Ann Word Pelvic Floor Disorders (2017). Urinary biomarkers in women with refractory urgency urinary incontinence randomized to sacral neuromodulation versus onabotulinumtoxinA compared to controls. Journal of Urology, 197(6), 1487-1494. https://doi.org/10.1016/j.juro.2017.01.037
Purpose: Wemeasured urinary biomarker levels inwomenwith refractory urgency urinary incontinence and controls at baseline and 6 months after treatment with sacral neuromodulation or intradetrusor injection of onabotulinumtoxinA. We also assessed the association of baseline biomarkers with posttreatment urgency urinary incontinence episodes and overactive bladder symptom bother outcomes.
Materials and Methods: First morning urine samples were collected from consented trial participants and age matched women without urgency urinary incontinence. Biomarkers reflecting general inflammation, neuroinflammation, afferent neurotransmitters and tissue remodeling were measured using standardized enzyme-linked immunosorbent assay and activity assays as appropriate. Symptombotherwas assessed by the overactive bladder questionnaire and urgency urinary incontinence episodes were determined by bladder diary. Linear models were used to examine differences in mean biomarker levels and the change in urgency urinary incontinence episodes and symptom bother between baseline and 6 months. Modest evidence of a potential association was represented by p = 0.01 and p = 0.004 represented moderate evidence of an association with outcomes.
Results: Baseline biomarker levels differed little between cases and controls except tropoelastin (p = 0.001) and N-terminal telopeptide collagen type 1 (p <0.001). Changes in biomarker levels 6 months after intervention included decreases in collagenase (p <0.001) in both treatment groups and increases in interleukin-8 (p = 0.002) and matrix metalloprotease-9 (p <0.001) in the onabotulinumtoxinA group. Higher baseline calcitonin gene-related peptide across both treatments (p = 0.007) and nerve growth factor in the onabotulinumtoxinA arm (p = 0.007) were associated with less reduction in overactive bladder symptom bother.
Conclusions: Refractory urgency urinary incontinence is a complex condition. These data suggest that matrix remodeling and neuropeptide mediation may be involved in its pathophysiological mechanisms and response to treatment.
